Y-mAbs: Pivotal Data for Omburtamab

 For 32 patients enrolled in the Company’s ongoing pivotal 101 multicenter study of omburtamab radiolabeled with Iodine-131, the results showed a twelve-month overall survival (“OS”) of 73.5%, with a median follow-up of 25 months. Further, the interim results showed an objective response rate (“ORR”) of 31.3% in the patients with measurable disease after central review based on Response Assessment in Neuro-Oncology (“RANO”) criteria and European Association of Neuro-Oncology (“EANO")/European Society for Medical Oncology (“ESMO”) criteria, and that a total of 75.0% of the patient with measurable disease achieved disease control. Serious Adverse Events (“SAE”) was found in 40.6% of the patients and were mostly related to myelosuppression.

https://www.biospace.com/article/releases/y-mabs-announces-pivotal-data-for-omburtamab/